Jaguar Health to present FDA-approved Gelclair for oral mucositis management at ASTRO Annual Meeting.

Jaguar Health Inc. will showcase Gelclair, an FDA-approved product for oral mucositis, at the ASTRO Annual Meeting in Washington, D.C. Gelclair helps manage oral lesions caused by chemotherapy and radiation, offering pain relief and improving patients' ability to eat and drink. The product, set to launch in the U.S. in October 2024, aims to address oral mucositis, a common and serious side effect affecting many cancer patients.

September 24, 2024
4 Articles